<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02015923</url>
  </required_header>
  <id_info>
    <org_study_id>01CCRe-IV</org_study_id>
    <secondary_id>2013-001688-22</secondary_id>
    <nct_id>NCT02015923</nct_id>
  </id_info>
  <brief_title>Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases</brief_title>
  <acronym>CCRe-IV</acronym>
  <official_title>Multicenter Randomized Study in Patients With Colorectal Cancer With Unresectable Metastases. Impact of Resection vs no Resection of the Primary Tumour as a Survival Factor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main outcome: Assess the impact of cancer-related survival at 2 years in patients with&#xD;
      unresectable metastatic colorectal cancer treated with chemotherapy alone versus surgery&#xD;
      followed by chemotherapy. To assess overall survival. To evaluate postoperative morbidity and&#xD;
      mortality in patients treated with resection of the primary tumor. Assess complications and&#xD;
      meed for surgery in patients treated with systemic chemotherapy only during the course of the&#xD;
      disease. Identify and describe the complications related to chemotherapy and toxicity in the&#xD;
      short and medium term systemic treatment. Assessing the quality of life questionnaire QLQ-C30&#xD;
      and QLQ-CR29. To study prognostic survival factors.&#xD;
&#xD;
      Method: multicenter randomized clinical trail (22 hospitals). Two parallel group in which to&#xD;
      evaluate two therapeutic strategies for colorectal cancer metastasis unresectable stage IV:&#xD;
      chemotherapy alone versus primary tumor resection plus chemotherapy.&#xD;
&#xD;
      Subjects: patients with unresectable nonmetastatic colorectal cancer. Hypothesis:Surgical&#xD;
      resection of the primary tumor in stage IV colorectal patients with unresectable synchronous&#xD;
      metastases increases by 14% overall survival compared to patients receiving systemic&#xD;
      treatment with chemotherapy without resection of the primary tumor (survival of 34% vs 20%).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention: Arm B (control): chemotherapy alone, regimen according to each center. Arm A&#xD;
      (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen&#xD;
      according to each center. Statistical Analysis: A power analysis showed that to assure a&#xD;
      significance level of 0,05 and a beta error 0.20. 168 patients are necessary in each arm. It&#xD;
      has been estimated a loss rate of up to 10%.&#xD;
&#xD;
      Differences between groups will be analyzed by t, U, X2, exact test and survival will be&#xD;
      assessed according to Kaplan and Meier method. Evaluation of safety of the trial will be made&#xD;
      in the middle of the study statistically&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties surrounding recruiting patients&#xD;
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the impact of overall survival in patients with unresectable metastatic colorectal cancer treated with chemotherapy alone vs surgery followed by chemotherapy.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The percentage of patients who are still alive for follow-up at 2 years after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity and mortality.</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>Postoperative complications were classified according to the Dindo-Clavien classification.&#xD;
Mortality within 30 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications in patients treated with systemic chemotherapy</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The toxicity will be evaluated and documented according to the CTCAE version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire Quality of life CR29</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Specific questionnaire for colon cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of possible survival factors</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Identify factors that may influence patient survival before applying any treatment (demographics, clinicals and analitycal factors, tumor characteristics; ...)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Colonic Cancer</condition>
  <condition>Unresectable Metastasis Originating in Colonic Cancer</condition>
  <arm_group>
    <arm_group_label>colonic resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B (control): chemotherapy alone, regimen according to each center</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonic resection</intervention_name>
    <description>Colonic cancer resection, R0 No surgical intervention on metastasis</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>colonic resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy- scheme</intervention_name>
    <description>Chemotherapy, specified in each center with or without biological drugs</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>colonic resection</arm_group_label>
    <other_name>FOLFOX-4</other_name>
    <other_name>FOLFOX-6</other_name>
    <other_name>FOLFIRI</other_name>
    <other_name>FOLFOXIRI</other_name>
    <other_name>CAPOX</other_name>
    <other_name>CETUXIMAX / BEVACIZUMAB/PANITUMUMAB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  colorectal cancer above to 12 cm from the anal verge&#xD;
&#xD;
          -  unresectable synchronous metastases&#xD;
&#xD;
          -  no contraindications for chemotherapy&#xD;
&#xD;
          -  absence of peritoneal carcinomatosis, central nervous system o bone metastasis.&#xD;
&#xD;
          -  performance status ECOG ≤ 2 (Eastern Cooperative Oncology Group)&#xD;
&#xD;
          -  uncontrolled concomitant medical conditions that may compromise to chemotherapy&#xD;
&#xD;
          -  significant symptomatic cardiac disease&#xD;
&#xD;
          -  not pregnancy or breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cases of rectal tumours below 12cm from anal verge, or locally advanced tumours&#xD;
             invading blood vessels, nerves or bone.&#xD;
&#xD;
          -  Multiple bone metastasis or central nervous system metastasis&#xD;
&#xD;
          -  Other neoplastic disease in the 5 previous years, except squamous or basal cell skin&#xD;
             carcinoma or cervical &quot;in situ&quot; carcinoma&#xD;
&#xD;
          -  Significant heart disease (chronic congestive heart failure, symptomatic coronary&#xD;
             disease) or myocardial infarction in the previous 6 months&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Patients who do not give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastiano Biondo, Sponsor</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Vaqué</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan García Armengol</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Mora</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporacion Parc Tauli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ignasi Camps Ausàs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Gemans Tiras i Pujol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Pera Román</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Univesitari del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Targarona Soler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorenzo Viso Pons</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Sant Joan Despí Moisès Broggi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Manuel Ramírez Rodríguez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Univeristario &quot;Lozano Blesa&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Julià Bergkvist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Girona DrJosep Trueta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa García Martínez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario de Vigo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Álvarez Gallego</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Univerisitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José María Enríquez Navascués</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Donostia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando de la Portilla de Juan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Angel Ciga</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eloy Espín Basany</last_name>
    <role>Principal Investigator</role>
    <affiliation>hospital Universitari de la Vall D'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Ferrer Márquez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Torrecárdenas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Abrisqueta Carrión</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Errasti Alustiza</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Araba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Parajó Calvo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario de Orense</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Moreno Sanz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario La Mancha Centro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejando Espí Macías</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricard Frago Montanuy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Araba</name>
      <address>
        <city>Vitoria/Gasteiz</city>
        <state>Araba</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08709</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario La Mancha Centro</name>
      <address>
        <city>Alcazar de San Juan</city>
        <state>Ciudad Real</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univesitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>Donostia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona DrJosep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univerisitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Orense</name>
      <address>
        <city>Ourense</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Univeristario &quot;Lozano Blesa&quot;</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>December 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Sebastiano Biondo</investigator_full_name>
    <investigator_title>Phd, MD</investigator_title>
  </responsible_party>
  <keyword>Colonic cancer</keyword>
  <keyword>Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

